MAGEA3 and melanoma: However, a tendency toward higher PFS was demonstrated among patients treated with cancer/testis targeting TCR-T (HR 0.91 95% CI, 0.64-1.3, P = .61) and, among these, patients treated with NYESO-1 targeting TCR therapy showed a significantly higher PFS compared to those treated with melanoma differentiation antigens or MAGE-A3 (HR 0.63 95% CI, 0.64-0.98, P = .03)—Supplementary Material S6.